Meta description: Is the 340B Drug Pricing Program going away? Learn what federal law says, why the program is changing, and what current legal and policy debates could mean.
The 340B Drug Pricing Program is not currently scheduled to end. Created by Congress in 1992, it requires participating drug manufacturers to offer discounted outpatient medicines to eligible health care organizations. But the program is under pressure from lawsuits, proposed policy changes, and disputes over how discounts are delivered and used. Those developments can make the future seem uncertain. The key distinction is that debate and change do not, by themselves, mean Congress has repealed the program. Here is what 340B does, what is driving the controversy, and what could happen next.
The 340B Drug Pricing Program is not currently going away simply because it faces litigation, criticism, or proposals for reform. It remains a federal program grounded in statute. The most realistic near-term uncertainty concerns how its rules are interpreted and applied, including contract-pharmacy arrangements, oversight, transparency, eligibility, and payment policy.
A complete end to 340B would require a major legal change, most likely congressional action. Until such a change is enacted, the program continues under existing law, while particular policies and disputes may evolve. For current decisions, covered entities, pharmacies, and patients should verify the latest HRSA guidance, enacted legislation, and court orders rather than relying on predictions or headlines.